Tiziana Life Sciences Ltd
NASDAQ:TLSABiotechnology
+$0.03 today
- Market cap
- $103.50M
- Beta
- 0.42
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.19
Volume 1.28M
Average 0.21M
TLSA Other Financing Activities
Financing cash flows not reported separately.
Tiziana Life Sciences LtdNASDAQ: TLSA
Other Financing Activities · Q4 FY2025 · quarter ended Dec 2025
Other financing activities grows 157.2% year over year
Q4 FY2025 other financing activities of $148K (cash outflow) rose 157.2% year over year. Over 3 fiscal years it compounded at +63.5% a year.
Context
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (196K) USD
- Year-over-year change
- -791.9%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (196K) | -791.9% |
| FY2024 | 2024-12-31 | 28.33K | +130.1% |
| FY2023 | 2023-12-31 | (94.17K) | -110.0% |
| FY2022 | 2022-12-31 | (44.84K) | +60.2% |
| FY2021 | 2021-12-31 | (112.67K) | — |
Other Financing Activities vs competitors
How TLSA compares with its peers on the latest reported figures
- TLSA's FY2025 other financing activities of $196K is the 5th largest of the 9 companies compared; the peer median is $0.
- Its year-over-year change of -791.9% is the 5th highest of 6, against a peer median of -100.0%.
- Over three fiscal years its annual growth of +63.5% compares with a peer median of +213.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $139.12M | +52398.9% | +394.4% | 88.6% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $111.31M | -85720.8% | — | 1557.8% |
| FY2025 | $1.71M | — | +33.0% | — | |
| LTM Mar 2026 | $1.45M | — | — | — | |
| FY2025 | $196K | -791.9% | +63.5% | — | |
| LTM Mar 2026 | $160.42K | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $0 | -100.0% | — | — |
| Peer median (excluding TLSA) | $0 | -100.0% | +213.7% | 88.6% | |
Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.36M) | (12.55M) | (14M) | (9.48M) | (18.43M) |
| Depreciation & Amortization | 104.52K | 41.57K | 75.97K | 99.09K | 234K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (573.01K) | (948.89K) | (1.25M) | (441.1K) | 3.06M |
| Accounts Receivables | 317.27K | (127.17K) | (1.14M) | (1.11M) | (692K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (890.27K) | (821.72K) | (109.21K) | 670.44K | 3.75M |
| Other Non-Cash Items | 1.7M | (2.53M) | 2.75M | 8.6M | 2.29M |
| Operating Cash Flow | (16.13M) | (15.99M) | (12.42M) | (1.22M) | (12.85M) |
| Capital Expenditures | (16.31K) | 0 | 0 | (15.18K) | (21K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (2.18M) | (791.35K) | (52K) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 112.67K | (1.08M) | (200.21K) | 10.45K | 3.06M |
| Investing Cash Flow | 96.37K | (3.26M) | (991.57K) | (56.74K) | 3.04M |
| Debt Repayment | 0 | 0 | 0 | (141K) | 0 |
| Common Stock Issued | 95.62K | 0 | 125.83K | 3.71M | 10.2M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (112.67K) | (44.84K) | (94.17K) | 28.33K | (196K) |
| Financing Cash Flow | (17.05K) | (44.84K) | 31.65K | 3.6M | 10.01M |
| Effect of Forex Changes | (1.53M) | (324.45K) | (22.16K) | (293.27K) | 84K |
| Net Change in Cash | (17.59M) | (19.62M) | (13.4M) | 2.03M | 286K |
| Free Cash Flow | (16.15M) | (15.99M) | (12.42M) | (1.23M) | (12.87M) |
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Intrinsic Alpha fair value
Locked
Current Price
$0.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.